GANX
Price
$1.11Alerts
Change
+$0.03 (+2.78%)
Updated
Nov 11 closing price
Capitalization
44.95M
140 days until earnings call
Intraday BUY SELL Signals
SLDB
Price
$7.60Alerts
Change
+$0.43 (+6.00%)
Updated
Nov 11 closing price
Capitalization
706.61M
124 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GANX vs SLDB

GANX vs SLDB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GANX vs. SLDB commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GANX is a Buy and SLDB is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GANX with price predictions
Nov 11, 2026

GANX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026

GANX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 34 cases where GANX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GANX's RSI Indicator exited the oversold zone, 28 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 71 cases where GANX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for GANX just turned positive on November 09, 2026. Looking at past instances where GANX's MACD turned positive, the stock continued to rise in 45 of 52 cases over the following month. The odds of a continued upward trend are 87%.

Following a +13.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where GANX advanced for three days, in 194 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GANX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for GANX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.981) is normal, around the industry mean (3.498). P/E Ratio (-2.060) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. GANX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GANX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for SLDB with price predictions
Nov 11, 2026

Momentum Indicator for SLDB turns positive, indicating new upward trend

SLDB saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 69 similar instances where the indicator turned positive. In 60 of the 69 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SLDB's RSI Oscillator exited the oversold zone, 30 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for SLDB just turned positive on October 21, 2026. Looking at past instances where SLDB's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.

SLDB moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +8.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in 200 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for SLDB moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLDB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

SLDB broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SLDB entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.889) is normal, around the industry mean (3.498). P/E Ratio (-3.487) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. SLDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
SLDB: Fundamental Ratings
SLDB
OUTLOOK RATING
1..100
31
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
48
P/E GROWTH RATING
1..100
20
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GANXSLDB
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
N/A
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 10 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (GANX: $1.11 vs. SLDB: $7.60)
Brand notoriety: GANX and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GANX: 57% vs. SLDB: 137%
Market capitalization -- GANX: $44.95M vs. SLDB: $706.61M
GANX [@Biotechnology] is valued at $44.95M. SLDB’s [@Biotechnology] market capitalization is $706.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GANX’s FA Score shows that 1 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).

  • GANX’s FA Score: 1 green, 4 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than GANX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GANX’s TA Score shows that 5 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).

  • GANX’s TA Score: 5 bullish, 2 bearish.
  • SLDB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, GANX is a better buy in the short-term than SLDB.

Price Growth

GANX (@Biotechnology) experienced а 0.00% price change this week, while SLDB (@Biotechnology) price change was +16.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

GANX is expected to report earnings on Apr 01, 2027.

SLDB is expected to report earnings on Mar 16, 2027.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

GANX and

Correlation & Price change

A.I.dvisor indicates that over the last year, GANX has been loosely correlated with COYA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if GANX jumps, then COYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GANX
1D Price
Change %
GANX100%
+2.78%
COYA - GANX
41%
Loosely correlated
+1.58%
VIR - GANX
38%
Loosely correlated
-0.15%
AXON - GANX
36%
Loosely correlated
+4.26%
BCYC - GANX
36%
Loosely correlated
N/A
SLDB - GANX
36%
Loosely correlated
+6.00%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LHSW3.620.22
+6.47%
Lianhe Sowell International Group Ltd
CGGG27.170.48
+1.80%
Capital Group U.S. Large Growth ETF
APCB28.50N/A
-0.02%
ActivePassive Core Bond ETF (APCB)
FTF5.46-0.02
-0.36%
Franklin Limited
MSFX26.27-1.23
-4.46%
T-Rex 2X Long Microsoft Daily Target ETF (MSFX)